MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based on 2019 PitchBook data. Dr. Susan Levinson co-founded BioAegis in 2011 and has been its CEO since its inception.

Read the full press release here: PitchBook

MORRISTOWN, NJ, (August 22, 2019) BioAegis Therapeutics, Inc., a clinical stage company developing technology to control inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of research results in the Journal of Infectious Diseases demonstrating that recombinant human plasma gelsolin therapy dramatically improves survival in a multidrug-resistant pneumonia animal model.   Furthermore, it works synergistically with previously ineffective antibiotics, making them work again.

Read the full press release here:  JID Publication Final 8-22-2019

MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring hospitalization because of Community-Acquired Pneumonia.
This blinded placebo-controlled trial was a dose-escalation study with four cohorts of 8 patients randomized 3:1 to recombinant gelsolin versus placebo. The highest-dose cohort receive 3 consecutive daily doses of 24 milligrams per kilogram of body weight. As anticipated, no serious or drug-related adverse events were reported in what were the highest doses ever administered to patients. Furthermore, analysis of the pharmacokinetics demonstrated that the product half-life exceeded 12 to 16 hours which supports once-daily dosing.

See the full release here: 2019 08 06 Phase 1b 2a Results

MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 30, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing recombinant human plasma gelsolin (pGSN) announced today that the United States Patent Office has issued a patent for the Use of Plasma Gelsolin to Diagnose and Treat Renal Failure.

Read the full press release here: Renal Patent 2019

MORRISTOWN, NJ (March 18, 2019). BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy for patients requiring hospitalization because of Community-Acquired Pneumonia (CAP).
A Novel Approach to Create a New Treatment Paradigm
Severe CAP is the lead indication of this clinical-stage company that addresses infectious, inflammatory and degenerative diseases with supplementation of an endogenous protein that is depressed in these disorders.
Patients were treated with recombinant human plasma gelsolin (rhu-pGSN) or a matching placebo in this blinded randomized clinical trial.

Read the full press release here: 2019 03 18 Completes Enrollment Phase 1b_2a